Siemens (NYSE:SI) Healthineers said today it inked a deal with Healthy.io looking to improve home chronic kidney disease monitoring.
Through the deal, the companies will look to offer a home-based alternative to periodic urine testing to monitor kidney function, which requires patients travel to a clinician’s office.
Siemens said it will supply urinalysis reagents which will be integrated into Healthy.io’s smartphone-based urinalysis system to provide home testing options to improve access to albumin-to-creatine ratio testing.
“Siemens Healthineers has been a leader in urinalysis testing for 75 years, enabling healthcare professionals around the world to test for chronic kidney disease and other conditions from the point of care to the central lab. This alliance expands our capabilities to improve patient experience by conducting testing in their home. Increased access to albumin-to-creatinine ratio testing—whether at home or at the physician’s office—is critical to reducing the economic burden of chronic disease and to improving patient outcomes,” Siemens point of care diagnostics exec VP Christoph Pedain said in a prepared statement.
“Healthy.io is a pioneer in using computer vision and machine learning to transform the smartphone camera into a clinical grade medical device for improved patient access and convenience. Healthy.io and Siemens Healthineers share a vision for a future of healthcare, which sees consumers take greater control of their healthcare in a way that complements the existing clinician workflow,” Healthy.io founder & CEO Yonatan Adiri said in a press release.
In August, Siemens and NuVasive inked a strategic partnership that will aim to develop and advance technology designed for minimally invasive spinal surgery.
